Pregled bibliografske jedinice broj: 714697
The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors
The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors // Medical hypotheses, 81 (2013), 6; 1155-1158 doi:10.1016/j.mehy.2013.09.030 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 714697 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The role of erythropoietin and erythropoietin receptor in malignant laryngeal tumors
Autori
Vukelić, Jelena ; Dobrila Dintinjana, Renata ; Jonjić, Nives ; Dekanić, Andrea ; Ilijić, Vjekoslav
Izvornik
Medical hypotheses (0306-9877) 81
(2013), 6;
1155-1158
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Erythropoetin; erythropoetin receptor; malignant laryngeal tumors
Sažetak
Erythropoietin (Epo) is a glycoprotein hormone responsible for erythropoiesis. Its effect is realized by binding erythropoietin receptor (EpoR) expressed on erythroid progenitor cells. Hypoxia is the main stimulus for the secretion of erythropoietin. Anemia is an independent negative prognostic factor for survival in patients with malignant diseases. Synthetic forms of erythropoietin are used in clinical oncology practice to increase the level of hemoglobin. As well as endogenous they can bind to EpoR. Considering the fact that most effects of synthetic Epo are negative, the role of endogenous Epo/EpoR has become an extremely important issue. The authors do not agree on most items related to the effects of exogenous Epo and EpoR in patients with head and neck carcinomas. We are investigating the expression of Epo/EpoR in the tissue of malignant laryngeal carcinoma. Our hypothesis is that less differentiated laryngeal carcinomas will have a higher level of endogenous Epo/EpoR expression. Therefore, in patients with positive Epo/EpoR we expect shorter survival and poorer locoregional disease control. We anticipate that our hypothesis may help to provide the role of endogenous Epo/EpoR in patients with malignant tumors of the larynx. If the assumptions of this study are confirmed, the patients with laryngeal carcinomas whose tumor cells express Epo/EpoR should not be considered for the treatment of anemia with recombinant erythropoietin in any case. We also point out that our research will expand the knowledge of the biology of laryngeal tumor cells and that the results could be utilized as basic knowledge in development of future therapeutic strategies.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Klinički bolnički centar Rijeka
Profili:
Renata Dobrila-Dintinjana
(autor)
Nives Jonjić
(autor)
Jelena Vukelić
(autor)
Andrea Dekanić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE